JP2023052027A5 - - Google Patents

Download PDF

Info

Publication number
JP2023052027A5
JP2023052027A5 JP2022205213A JP2022205213A JP2023052027A5 JP 2023052027 A5 JP2023052027 A5 JP 2023052027A5 JP 2022205213 A JP2022205213 A JP 2022205213A JP 2022205213 A JP2022205213 A JP 2022205213A JP 2023052027 A5 JP2023052027 A5 JP 2023052027A5
Authority
JP
Japan
Prior art keywords
group
compound
carbon atoms
solvate
hydrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022205213A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023052027A (ja
Filing date
Publication date
Priority claimed from JP2020501434A external-priority patent/JP2020512400A/ja
Application filed filed Critical
Publication of JP2023052027A publication Critical patent/JP2023052027A/ja
Publication of JP2023052027A5 publication Critical patent/JP2023052027A5/ja
Pending legal-status Critical Current

Links

JP2022205213A 2017-03-23 2022-12-22 TGFβの阻害のための三置換イミダゾールおよび治療方法 Pending JP2023052027A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762475451P 2017-03-23 2017-03-23
US62/475,451 2017-03-23
JP2020501434A JP2020512400A (ja) 2017-03-23 2018-03-23 TGFβの阻害のための三置換イミダゾールおよび治療方法
PCT/US2018/024133 WO2019005241A1 (en) 2017-03-23 2018-03-23 TRI-SUBSTITUTED IMIDAZOLES FOR INHIBITION OF TGF-BETA AND METHODS OF TREATMENT

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2020501434A Division JP2020512400A (ja) 2017-03-23 2018-03-23 TGFβの阻害のための三置換イミダゾールおよび治療方法

Publications (2)

Publication Number Publication Date
JP2023052027A JP2023052027A (ja) 2023-04-11
JP2023052027A5 true JP2023052027A5 (cg-RX-API-DMAC10.html) 2023-08-07

Family

ID=64741862

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020501434A Pending JP2020512400A (ja) 2017-03-23 2018-03-23 TGFβの阻害のための三置換イミダゾールおよび治療方法
JP2022205213A Pending JP2023052027A (ja) 2017-03-23 2022-12-22 TGFβの阻害のための三置換イミダゾールおよび治療方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2020501434A Pending JP2020512400A (ja) 2017-03-23 2018-03-23 TGFβの阻害のための三置換イミダゾールおよび治療方法

Country Status (5)

Country Link
US (2) US11124509B2 (cg-RX-API-DMAC10.html)
EP (1) EP3600294B1 (cg-RX-API-DMAC10.html)
JP (2) JP2020512400A (cg-RX-API-DMAC10.html)
ES (1) ES3053505T3 (cg-RX-API-DMAC10.html)
WO (1) WO2019005241A1 (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3053505T3 (en) * 2017-03-23 2026-01-22 Clavius Pharmaceuticals Llc Tri-substituted imidazoles for the inhibition of tgf beta and methods of treatment
WO2020041562A1 (en) 2018-08-22 2020-02-27 Clavius Pharmaceuticals, Llc Substituted imidazoles for the inhibition of tgf-beta and methods of treatment
CA3117710A1 (en) 2018-12-11 2020-06-18 Theravance Biopharma R&D Ip, Llc Alk5 inhibitors
KR20220104208A (ko) 2019-11-22 2022-07-26 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 Alk5 억제제로서 치환된 1,5-나프티리딘 또는 퀴놀린
KR102509625B1 (ko) * 2022-03-25 2023-03-14 주식회사 메드팩토 TGF-β 저해제의 합성에 유용한 중간체 및 이를 이용한 TGF-β 저해제 제조방법
AU2023449764A1 (en) * 2023-05-22 2025-12-11 Iregene Therapeutics Co., Ltd. Pyrazolecarbonyl piperazinone compound, pharmaceutical composition and use thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001163861A (ja) * 1999-12-07 2001-06-19 Nippon Soda Co Ltd ジフェニルイミダゾール化合物および農園芸用殺菌剤
NZ549003A (en) * 2004-03-05 2009-07-31 Taisho Pharmaceutical Co Ltd Thiazole derivative as an ALK5 inhibitor
US8188113B2 (en) * 2006-09-14 2012-05-29 Deciphera Pharmaceuticals, Inc. Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
WO2008094556A2 (en) * 2007-01-30 2008-08-07 Biogen Idec Ma Inc. Imidazolone compounds as tgf-beta family type i receptors, alk5 and/or alk4 antagonists
AU2009226136B2 (en) * 2008-03-17 2013-08-15 Ambit Biosciences Corporation Quinazoline derivatives as RAF kinase modulators and methods of use thereof
WO2009115572A2 (en) 2008-03-21 2009-09-24 Novartis Ag Novel heterocyclic compounds and uses therof
CN102131801B (zh) * 2008-06-25 2015-04-08 福拉姆医药股份有限公司 1,2-二取代的杂环化合物
JP2012514044A (ja) * 2008-12-30 2012-06-21 ミレニアム ファーマシューティカルズ, インコーポレイテッド Rafキナーゼ阻害剤として有用なヘテロアリール化合物
US8080568B1 (en) 2010-06-29 2011-12-20 Ewha University - Industry Collaboration Foundation 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors
US20120252721A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
RU2612958C2 (ru) 2011-07-13 2017-03-14 Ск Кемикалз Ко., Лтд. 2-пиридилзамещенные имидазолы в качестве ингибиторов alk5 и/или alk4
JO3336B1 (ar) * 2014-10-07 2019-03-13 Lilly Co Eli مركبات أمينو بيريديلوكسي بيرازول
EP3221318B1 (en) 2014-11-21 2021-08-25 Rigel Pharmaceuticals, Inc. Fused imidazole derivatives as tgf-beta inhibitors
JP6836998B2 (ja) * 2015-03-02 2021-03-03 ライジェル ファーマシューティカルズ, インコーポレイテッド TGF−β阻害剤
WO2018068759A1 (zh) 2016-10-14 2018-04-19 江苏恒瑞医药股份有限公司 五元杂芳环并桥环类衍生物、其制备方法及其在医药上的应用
ES3053505T3 (en) 2017-03-23 2026-01-22 Clavius Pharmaceuticals Llc Tri-substituted imidazoles for the inhibition of tgf beta and methods of treatment

Similar Documents

Publication Publication Date Title
JP2023533203A5 (cg-RX-API-DMAC10.html)
JP2023513680A5 (cg-RX-API-DMAC10.html)
JP2022512588A5 (cg-RX-API-DMAC10.html)
RU2125566C1 (ru) Производные пиперазина, способы их получения
JP2019537559A5 (cg-RX-API-DMAC10.html)
JP2013542213A5 (cg-RX-API-DMAC10.html)
JP2023531709A5 (cg-RX-API-DMAC10.html)
JP2006521359A5 (cg-RX-API-DMAC10.html)
JP2010516635A5 (cg-RX-API-DMAC10.html)
RU2008105345A (ru) Производные имида индолилмалеиновой кислоты как ингибиторы протеинкиназы с
JP2007519695A5 (cg-RX-API-DMAC10.html)
JP2022519239A5 (cg-RX-API-DMAC10.html)
JP2006524222A5 (cg-RX-API-DMAC10.html)
JP2020512400A5 (cg-RX-API-DMAC10.html)
JP2012530765A5 (cg-RX-API-DMAC10.html)
FR2655988A1 (fr) Nouveaux derives de la napht-1-yl piperazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
JP2020517677A5 (cg-RX-API-DMAC10.html)
JP2023531495A5 (cg-RX-API-DMAC10.html)
JP2024526191A5 (cg-RX-API-DMAC10.html)
RU2010113358A (ru) Гуанидинсодержащие соединения, применимые в качестве антагонистов мускариновых рецепторов
JP2017519796A5 (cg-RX-API-DMAC10.html)
JP2004520285A5 (cg-RX-API-DMAC10.html)
JP2022533939A5 (cg-RX-API-DMAC10.html)
JP2006522797A5 (cg-RX-API-DMAC10.html)
RU2010147938A (ru) Способ получения промежуточных соединений нафталин-2-ид-пиразол-3-она, используемых в синтезе ингибиторов сигма рецептора